Tpoxx
(Tecovirimat)ApprovedSmall molecule
Tpoxx is a small molecule that works as a VP37 Inhibitor.[2] It is being used across 1 indication, with its most advanced program in Approved.[1]
Tpoxx is one of 2 small molecule programs targeting Mpox. It is currently in Approved.
1
Indications
10
Total Trials
3
Active Trials
1
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
8
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Mpox
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Tecovirimat for Treatment of Monkeypox Virus
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05559099·597 enrolled
Efficacy and Safety1 trial
Immunogenicity1 trial
4 more indications
Regulatory
FDA Approval Timeline[4]
Jul 13, 2018
TPOXX
NDA NDA208627
May 18, 2022
TPOXX
NDA NDA214518
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tecovirimat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Tpoxx. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- VP37 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSIGA Technologies